PYY1875 / Novo Nordisk - LARVOL DELTA

Variant screening of PYY3-36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity. (PubMed, Sci Transl Med) - "One of the tested analogs, PYY1875, has progressed into clinical trials for obesity. Together, our results demonstrate the power of variant screening combined with fatty diacid derivatization in the development of a long-acting, highly efficacious PYY clinical candidate."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (clinicaltrials.gov) - P2 | N=119 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed | Trial primary completion date: May 2022 ➔ Dec 2022

Combination therapy • Trial completion • Trial primary completion date • Genetic Disorders • Obesity

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (clinicaltrials.gov) - P2 | N=114 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Genetic Disorders • Obesity

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (clinicaltrials.gov) - P2; N=114; Recruiting; Sponsor: Novo Nordisk A/S; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Genetic Disorders • Obesity

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (clinicaltrials.gov) - P2; N=114; Not yet recruiting; Sponsor: Novo Nordisk A/S

Clinical • Combination therapy • New P2 trial • Genetic Disorders • Obesity